956 Glioma-neuronal circuit remodeling induces regional immunosuppression

956 Glioma-neuronal circuit remodeling induces regional immunosuppression

Bibliographic Details
Main Authors:	Hideho Okada, Tiffany Chen, Takahide Nejo, Akane Yamamichi, Shawn L Hervey-Jumper, Su Phyu, Saritha Krishna, Christian Jimenez, Jacob S Young, Senthilnath Lakshmanachetty, Payal Watchmaker, Abrar Choudhury, David R Raleigh
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
by: Marco Gallus, et al.
Published: (2023-07-01)

Correction: Gallus et al. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma. <i>Cancers</i> 2023, <i>15</i>, 3726
by: Marco Gallus, et al.
Published: (2023-12-01)

277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma
by: Yuan Wang, et al.
Published: (2023-11-01)

Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma
by: Takahide Nejo, et al.
Published: (2024-03-01)

843 Intra-cerebral spinal fluid vaccination to facilitate antigen-specific T-cell responses in the CNS tumors
by: Hideho Okada, et al.
Published: (2023-11-01)

New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs
by: Senthilnath Lakshmanachetty, et al.
Published: (2021-04-01)

144 Novel public and tumor-wide neoantigens arising from clonal aberrant splicing events drive tumor-specific T-cell responses across diverse cancer types
by: Gary Chan, et al.
Published: (2023-11-01)

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
by: Hirokazu Ogino, et al.
Published: (2022-02-01)

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
by: Lisa H Butterfield, et al.
Published: (2023-03-01)

Editorial: Quality of care of glioma patients
by: Marie-Therese Forster, et al.
Published: (2022-10-01)

Corrigendum: Editorial: Quality of care of glioma patients
by: Marie-Therese Forster, et al.
Published: (2022-12-01)

Involvement of White Matter Language Tracts in Glioma: Clinical Implications, Operative Management, and Functional Recovery After Injury
by: Alexander A. Aabedi, et al.
Published: (2022-07-01)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
by: Pavlina Chuntova, et al.
Published: (2019-01-01)

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
by: Sabine Mueller, et al.
Published: (2022-06-01)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
by: Brian J. Ahn, et al.
Published: (2013-11-01)

5-ALA in Suspected Low-Grade Gliomas: Current Role, Limitations, and New Approaches
by: Barbara Kiesel, et al.
Published: (2021-07-01)

Hypoxia potentiates glioma-mediated immunosuppression.
by: Jun Wei, et al.
Published: (2011-01-01)

The mechanism of immunosuppression in patients with brain glioma
by: V A Frolov, et al.
Published: (2014-12-01)

The evolution of alternative splicing in glioblastoma under therapy
by: Lin Wang, et al.
Published: (2021-01-01)

Preclinical modeling of lower-grade gliomas
by: Lilly W. Tang, et al.
Published: (2023-03-01)

The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy
by: Zeyu Wang, et al.
Published: (2021-09-01)

TCGA mRNA Expression Analysis of the Heme Biosynthesis Pathway in Diffusely Infiltrating Gliomas: A Comparison of Typically 5-ALA Fluorescent and Non-Fluorescent Gliomas
by: Mario Mischkulnig, et al.
Published: (2020-07-01)

Neuro-Oncology Patients as Human Research Subjects: Ethical Considerations for Cognitive and Behavioral Testing for Research Purposes
by: Jasleen Kaur, et al.
Published: (2022-01-01)

370 Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies
by: Michael McDermott, et al.
Published: (2023-11-01)

Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma
by: Qianquan Ma, et al.
Published: (2018-12-01)

In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging.
by: Jia Zhong, et al.
Published: (2013-01-01)

Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas
by: Mario Mischkulnig, et al.
Published: (2021-02-01)

Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions
by: Junfeng Liu, et al.
Published: (2023-05-01)

Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma
by: Tareq M. Haedenkamp, et al.
Published: (2020-02-01)

Targeting FGL2 in glioma immunosuppression and malignant progression
by: Xiaoyu Ma, et al.
Published: (2022-10-01)

Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
by: Fujita Mitsugu, et al.
Published: (2007-12-01)

Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology
by: Melike Pekmezci, et al.
Published: (2021-06-01)

Electrical and synaptic integration of glioma into neural circuits
by: Venkatesh, Humsa S., et al.
Published: (2020)

Porcine-human glioma xenograft model. Immunosuppression and model reproducibility
by: P.Jack Hoopes, et al.
Published: (2024-01-01)

EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines
by: Manabu Hatano, et al.
Published: (2005-08-01)

Gasdermin D Plays an Oncogenic Role in Glioma and Correlates to an Immunosuppressive Microenvironment
by: Mengyuan Li, et al.
Published: (2023-05-01)

TANK shapes an immunosuppressive microenvironment and predicts prognosis and therapeutic response in glioma
by: Shasha Li, et al.
Published: (2023-05-01)

In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment
by: Yang Liu, et al.
Published: (2023-06-01)

Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
by: Andrea Franson, et al.
Published: (2022-09-01)

Importance of iatrogenic immunosuppression in the treatment of patients with high-grade glioma with immunotherapy
by: Anna F Piotrowski, et al.
Published: (2019-01-01)